Flexion CEO Makes The Case For Zilretta
Flexion CEO Mike Clayman shares expectations for Zilretta for knee osteoarthritis and discusses plans for commercialization in an interview at the Biotech Showcase in January.
You may also be interested in...
FDA labeling in knee pain osteoarthritis is favorable for long-acting steroid Zilretta and a sales force is lined up, but Flexion has its commercial work cut out competing with very cheap generics.
OncoMed lays off half its employees after a series of recent clinical setbacks. Meanwhile, six public companies raise $1.64bn in $100m-plus follow-on and debt offerings, SV Health Investors closed a $400m venture capital fund and eight therapeutics firms grabbed $247.5m in VC cash.
Burlington, Mass.-based Flexion Therapeutics Inc.'s long-acting steroid injection Zilretta has been associated with statistically significant improvements in pain relief in a pivotal Phase III study in patients with knee osteoarthritis, countering disappointing results from a Phase IIb study reported last year and keeping the product in line for a US NDA submission in the second half on 2016.